The stock of CytomX Therapeutics Inc (NASDAQ:CTMX) is a huge mover today! About 220,813 shares traded hands or 154.02% up from the average. CytomX Therapeutics Inc (NASDAQ:CTMX) has declined 14.55% since April 6, 2016 and is downtrending. It has underperformed by 16.50% the S&P500.
The move comes after 5 months negative chart setup for the $391.52M company. It was reported on Nov, 8 by Barchart.com. We have $9.09 PT which if reached, will make NASDAQ:CTMX worth $50.90 million less.
Analysts await CytomX Therapeutics Inc (NASDAQ:CTMX) to report earnings on November, 28. They expect $-0.36 EPS, up 97.48% or $13.90 from last year’s $-14.26 per share. After $-0.39 actual EPS reported by CytomX Therapeutics Inc for the previous quarter, Wall Street now forecasts -7.69% EPS growth.
CytomX Therapeutics Inc (NASDAQ:CTMX) Ratings Coverage
Out of 3 analysts covering CytomX Therapeutics (NASDAQ:CTMX), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. CytomX Therapeutics has been the topic of 3 analyst reports since November 2, 2015 according to StockzIntelligence Inc. Oppenheimer initiated the stock with “Outperform” rating in Monday, November 2 report. Cowen & Co initiated the stock with “Outperform” rating in Monday, November 2 report. The firm has “Buy” rating given on Monday, November 2 by Jefferies.
According to Zacks Investment Research, “CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.”
More important recent CytomX Therapeutics Inc (NASDAQ:CTMX) news were published by: Marketwatch.com which released: “CytomX Therapeutics Inc.” on September 01, 2015, also Quotes.Wsj.com published article titled: “News CytomX Therapeutics Inc.CTMX”, Globenewswire.com published: “CytomX Therapeutics Announces Third Quarter 2016 Financial Results and …” on November 03, 2016. More interesting news about CytomX Therapeutics Inc (NASDAQ:CTMX) was released by: Medgadget.com and their article: “CytomX Therapeutics, Inc Pipeline Review, Industry Analysis, Size and Clinical …” with publication date: October 26, 2016.
CTMX Company Profile
CytomX Therapeutics, Inc., incorporated on October 16, 2010, is an oncology-focused biopharmaceutical company. The Firm is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. The Firm uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets. The Company’s Probody therapeutics are designed to take advantage of the conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. A Probody therapeutic consists of three components produced as a single protein by standard antibody production methodology: an active anti-cancer antibody, a mask for the antibody and a protease-cleavable linker. When a Probody therapeutic enters a tumor, it encounters proteases, which are enzymes that cleave proteins and are active primarily in the tumor microenvironment. The proteases in the tumor cleave the linker, releasing the mask and allowing the antibody to attack the tumor. The Company’s Probody candidates are designed to be produced as fully recombinant antibody prodrugs.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.